Next-Generation Nanovector Systems for Personalized Medicine
Legal Citation
Summary of the Inventive Concept
The next-generation nanovector system enables targeted delivery of multiple active substances, leveraging computational frameworks and personalized nanoparticle libraries to revolutionize disease treatment.
Background and Problem Solved
The original patent disclosed nanovectors for delivering active substances, but was limited to single-substance delivery and lacked personalized targeting capabilities. The new inventive concept addresses these limitations by introducing a modular, computational framework-driven approach to nanovector design, enabling tailored therapy for individual patients.
Detailed Description of the Inventive Concept
The next-generation nanovector system comprises a plurality of polysiloxane-based nanoparticles with distinct surface chemistries, each optimized for a specific active substance. A computational framework predicts optimal nanoparticle-substance combinations, and a method for generating personalized nanovector libraries involves analyzing a patient's genetic profile and identifying target active substances. The system also includes a nanovector-based therapeutic platform with stimuli-responsive elements and modular designs for adaptable therapy.
Novelty and Inventive Step
The new claims introduce a paradigm shift in nanovector technology by enabling multi-substance delivery, personalized targeting, and modular design. The computational framework and nanoparticle library generation method are novel and non-obvious, providing a significant inventive step beyond the original patent.
Alternative Embodiments and Variations
Alternative embodiments could include varying nanoparticle core materials, different targeting moieties, or incorporation of additional stimuli-responsive elements. Variations could also involve adapting the computational framework for different disease types or patient populations.
Potential Commercial Applications and Market
The next-generation nanovector system has significant commercial potential in the personalized medicine market, particularly in the treatment of complex diseases such as cancer and genetic disorders. Target industries include pharmaceutical companies, biotechnology firms, and medical research institutions.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K38/31 |
| A | A61 | A61K9/146 |
| A | A61 | A61K31/704 |
| A | A61 | A61K33/243 |
| A | A61 | A61K33/244 |
| A | A61 | A61K47/6929 |
| A | A61 | A61K49/0002 |
| A | A61 | A61K49/128 |
| A | A61 | A61K49/1881 |
| A | A61 | A61P35/00 |
| B | B82 | B82Y5/00 |
| A | A61 | A61K9/0019 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Nanomedicine and targeted drug delivery systems, specifically nanovector technologies for therapeutic substance transport, requiring advanced knowledge in materials science, surface chemistry, nanotechnology, and pharmaceutical formulation
Person of Ordinary Skill (PHOSITA) Profile
A PhD-level researcher with expertise in nanomaterials engineering, having advanced training in polymer chemistry, surface modification techniques, and drug delivery system design, with access to computational modeling and synthetic chemistry resources
Obviousness Rationale
A PHOSITA would recognize that the PTD's computational framework and personalized nanovector library approach represent predictable extensions of the source patent's foundational nanovector technology. The disclosed variations leverage known techniques in surface chemistry, computational prediction, and modular nanoparticle design to create a more sophisticated drug delivery platform. The incremental improvements in targeting, multi-substance delivery, and personalization would be considered obvious refinements to an existing nanovector system.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,604 |
|---|---|
| Title | Nanovectors and uses |
| Assignee(s) | NH THERAGUIX |